University of Maryland BioPark, Life Sciences Conference Center
801 W. Baltimore Street, Baltimore, MD 21202
Meet with Bahija Jallal, Ph.D., Executive Vice President of Research and Development, MedImmune
The Changing Face of the Biopharmaceutical Industry—Creating a Culture of Innovation
The biopharmaceutical industry is not the same as it was even a decade ago. Today, there are even more pressures to produce not just safe and effective drugs but safe and effective drugs that the payers are willing to pay for. We also know that research and development costs are increasing while R&D productivity continues to be on the decline. How can we continue to make it in the industry when our ultimate goal is to provide much needed drugs to patients with unmet medical needs?
The Program:
1 – Analyzing the current state of the biopharmaceutical industry
2 – Creating a Culture of innovation
3 – Managing uncertainty, strategic options, and decision making to Impact the Bottom Line
4 – Analyzing the current state of the biopharmaceutical industry
5 – Analyzing the current state of the biopharmaceutical industry by looking at industry trends and addressing some of the challenges that the industry is currently facing.
The Speaker:
Dr. Jallal is a member of both MedImmune’s executive team as well as the R&D leadership team of parent company AstraZeneca. She joined MedImmune as Vice President, Translational Sciences, in March 2006 and has since held positions of increasing responsibility. Dr. Jallal now oversees research, development, regulatory and clinical activities conducted by a team of more than 2,500 employees based at MedImmune’s Maryland, California, and Cambridge, UK sites. Dr. Jallal has guided the MedImmune R&D organization through unprecedented growth and expansion of its biologics pipeline from 40 drugs to more than 140. Dr. Jallal is passionate about leading and shaping MedImmune’s rich pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardio-vascular and gastrointestinal disorders and pain to ultimately develop new medicines for patients.
In addition to working with the State of Maryland as a board member for the UM Health Sciences RPC, Dr. Jallal participated last year in Maryland Governor O'Malley's Trade Mission to India where she represented the life sciences. She has authored more than 60 peer-reviewed publications and has over 15 patents. She is a member of multiple research associations and organizations promoting women in science. In 2011 she was named one of FierceBiotech's Top Women in Biotech.
Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc. where she held positions of increasing responsibility leading to Senior Director, Research.
Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
